CJC-1295 Side Effects: The Complete List and How to Handle Them

CJC-1295 at a glance:

• Drug class: Long-acting GHRH analog (research peptide)
• Route: subcutaneous injection (research use)
• Typical frequency: varies; once weekly (DAC) or daily (no-DAC) in user protocols
• Half-life: approximately 6-8 days (DAC version); ~30 minutes (no-DAC version)

CJC-1295's side-effect profile follows the same general pattern as other long-acting ghrh analog (research peptide)s. The list below is honest about both the common and the serious.

Common Side Effects of CJC-1295

The side effects most often reported with CJC-1295:

• Injection-site reactions — usually minor redness or itching; rotating injection sites helps.
• Transient flushing — transient warming of the skin; typically resolves within minutes.
• Headache — typically mild and self-limited; persists in only a small minority of users.

These tend to be dose-related. They are most prominent during dose escalation and typically improve once the body adapts to a steady dose.

Serious Risks

Less common but important:

• Fluid retention — see the prescribing information for full risk language for details. Notify your clinician promptly if relevant symptoms develop.
• Carpal tunnel symptoms — see the prescribing information for full risk language for details. Notify your clinician promptly if relevant symptoms develop.
• Potential effect on glucose metabolism — see the prescribing information for full risk language for details. Notify your clinician promptly if relevant symptoms develop.
• Supply-chain contamination from unregulated suppliers — see the prescribing information for full risk language for details. Notify your clinician promptly if relevant symptoms develop.

How to Manage Common Side Effects

Track what you feel. Side effects are easier to discuss when you have a record of when they appear and how severe they are.

Don't change the dose on your own. Many side effects improve with time at a steady dose; stopping and restarting often resets the adaptation period.

Stay hydrated and eat regularly. Generic advice that nonetheless prevents many otherwise-avoidable side-effect calls.

Communicate with your clinician. Most side effects have a management strategy; the worst outcomes happen when people stop the drug silently and don't get the next-step plan.

For dose-titration questions, see our CJC-1295 dosage guide.

Side Effects vs. Withdrawal Effects

It's worth distinguishing between side effects (from taking the drug) and withdrawal or rebound effects (from stopping it). For CJC-1295, the most relevant rebound concern is compound-specific — see the prescribing information.

When to Stop and Call Someone

These symptoms warrant prompt clinical evaluation:

• Severe abdominal pain (especially radiating to the back) — possible pancreatitis
• Vision changes
• Signs of allergic reaction (hives, throat tightness, difficulty breathing)
• Severe vomiting or dehydration
• Persistent symptoms that worsen rather than improve

Side Effects in Context

Most people who take CJC-1295 experience some side effects. Most of those are tolerable and improve with time. The decision to continue is a balance between benefit and tolerance, made together with a clinician.

For people weighing whether CJC-1295 is the right fit, our CJC-1295 results page covers the upside.

Bottom Line

Side effects on CJC-1295 are part of the trade-off, not a sign you're doing something wrong. The honest read is that most are tolerable and most improve.

Frequently Asked Questions

Related Reading

• CJC-1295 101: A Plain-English Guide for 2026
• Does CJC-1295 Really Work? An Evidence-Based Results Review
• The Real CJC-1295 Price Tag in 2026 — With and Without Insurance
• CJC-1295 Cycles Explained: Where the Evidence Stops
• The Honest Guide to MK-677: What Patients and Doctors Actually Say
• Is MK-677 Safe? An Honest Look at the Side-Effect Profile

Sources

• Stanley TL et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients With Lipodystrophy. NEJM 2010;363:2425.
• Nass R et al. Effects of an Oral Ghrelin Mimetic on Body Composition in Healthy Older Adults. Annals of Internal Medicine 2008;149:601.
• Teichman SL et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295. JCEM 2006;91:799.

This page is informational only and is not medical advice. Stop CJC-1295 and seek medical attention if you experience severe symptoms.